Jiang Cao

List of Publications by Year in descending order

81 papers	1,848 citations	331670 21 h-index	330143 37 g-index
99 all docs	99 docs citations	99 times ranked	2428 citing authors

#	Article	IF	Citations
1	Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells. Transplantation and Cellular Therapy, 2022, 28, 118.e1-118.e5.	1.2	4
2	Safety and efficacy of a humanized <scp>CD19</scp> chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology, 2022, 97, 711-718.	4.1	3
3	Efficacy and safety of CD19-specific CAR T cellâ€“based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood, 2022, 139, 3376-3386.	1.4	36
4	Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 2246-2256.	1.6	43
5	Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma. Frontiers in Immunology, 2022, 13, 814548.	4.8	7
6	Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia, 2021, 35, 1563-1570.	7.2	49
7	Kinetics of immune reconstitution after antiâ€CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients. International Journal of Laboratory Hematology, 2021, 43, 250-258.	1.3	14
8	A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Science Translational Medicine, 2021, 13, .	12.4	49
9	Humanized <scp>CD19</scp>â€targeted chimeric antigen receptor <scp>T</scp> (<scp>CARâ€T</scp>) cells for relapsed/refractory pediatric acute lymphoblastic leukemia. American Journal of Hematology, 2021, 96, E162-E165.	4.1	12
10	Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Frontiers in Immunology, 2021, 12, 611366.	4.8	41
11	Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 273.e1-273.e5.	1.2	4
12	Caspase-1 inhibition ameliorates murine acute graft versus host disease by modulating the Th1/Th17/Treg balance. International Immunopharmacology, 2021, 94, 107503.	3.8	1
13	Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient. International Journal of Hematology, 2021, 114, 408-412.	1.6	4
14	Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study. Journal of Affective Disorders, 2021, 286, 33-39.	4.1	6
15	An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study. Frontiers in Oncology, 2021, 11, 691064.	2.8	15
16	Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Blood Advances, 2021, 5, 5290-5299.	5.2	40
17	Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy. Frontiers in Immunology, 2021, 12, 755549.	4.8	12
18	Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia. Journal of Cellular and Molecular Medicine, 2021, 25, 11063-11074.	3.6	12

#	Article	IF	Citations
19	Treatment outcome of 301 aplastic anemia patients in China: a 10-year follow-up and real-world data from single institute experience. Hematology, 2021, 26, 1025-1030.	1.5	3
20	Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 865-875.	2.0	51
21	Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment. Bone Marrow Transplantation, 2020, 55, 2215-2218.	2.4	8
22	Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. Leukemia, 2020, 34, 2704-2707.	7.2	21
23	Phase II trial of coâ€administration of CD19â€and CD20â€targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Medicine, 2020, 9, 5827-5838.	2.8	36
24	TIRC7 inhibits Th1ï¿½cells by upregulating the expression of CTLAâ€'4 and STAT3 in mice with acute graftâ€'versusâ€'host disease. Oncology Reports, 2020, 44, 43-54.	2.6	4
25	A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematology,the, 2019, 6, e521-e529.	4.6	211
26	Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia. Leukemia, 2019, 33, 2751-2753.	7.2	12
27	Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells. International Journal of Biological Macromolecules, 2019, 137, 1030-1040.	7.5	8
28	Downregulation of long non-coding RNA TUG1 suppresses tumor growth by promoting ubiquitination of MET in diffuse large B-cell lymphoma. Molecular and Cellular Biochemistry, 2019, 461, 47-56.	3.1	20
29	miR-302 cluster inhibits angiogenesis and growth of K562 leukemia cells by targeting VEGFA. OncoTargets and Therapy, 2019, Volume 12, 433-441.	2.0	9
30	Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia. International Journal of Biological Macromolecules, 2019, 136, 209-219.	7.5	6
31	FN1, SPARC, and SERPINE1 are highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma revealed by microarray and bioinformatics. Scientific Reports, 2019, 9, 7827.	3.3	141
32	High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia. Cancer Cell International, 2019, 19, 122.	4.1	6
33	Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia. Annals of Hematology, 2019, 98, 2009-2011.	1.8	5
34	High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia. Journal of Translational Medicine, 2019, 17, 106.	4.4	10
35	Emerging role of stem cell memoryâ€like T cell in immune thrombocytopenia. Scandinavian Journal of Immunology, 2019, 89, e12739.	2.7	13
36	Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia. International Journal of Biological Macromolecules, 2019, 124, 1123-1131.	7.5	7

#	Article	IF	Citations
37	Advantages of digital PCR in the detection of low abundance BCRâ€'ABL1 gene in patients with chronic myeloid leukemia. Oncology Letters, 2019, 18, 5139-5144.	1.8	2
38	Potent antiâ€leukemia activities of humanized CD19â€targeted Chimeric antigen receptor T (CARâ€T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology, 2018, 93, 851-858.	4.1	138
39	GTPBP4 Promotes Gastric Cancer Progression via Regulating P53 Activity. Cellular Physiology and Biochemistry, 2018, 45, 667-676.	1.6	19
40	Mutation of the conserved G66 residue in GS region decreased structural stability and activity of arginine kinase. International Journal of Biological Macromolecules, 2018, 111, 247-254.	7.5	1
41	Roles of amino acid residues H66 and D326 in the creatine kinase activity and structural stability. International Journal of Biological Macromolecules, 2018, 107, 512-520.	7.5	1
42	NANOGP8 expression regulates gastric cancer cell progression by transactivating DBC1 in gastric cancer MKNâ€'45 cells. Oncology Letters, 2018, 17, 555-563.	1.8	8
43	MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy. Journal of Translational Medicine, 2018, 16, 267.	4.4	15
44	Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms. International Journal of Biological Macromolecules, 2018, 116, 1064-1073.	7.5	13
45	Effects of JAK2 V556F mutation on the JAK2's activity, structural stability and the transformation of Ba/F3 cells. International Journal of Biological Macromolecules, 2018, 117, 271-279.	7.5	5
46	CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia. Cell Death and Disease, 2018, 9, 774.	6.3	17
47	Efficacy of orlistat in nonâ€'alcoholic fatty liver disease: A systematic review and metaâ€'analysis. Biomedical Reports, 2018, 9, 90-96.	2.0	29
48	The Human RNA Surveillance Factor UPF1 Modulates Gastric Cancer Progression by Targeting Long Non-Coding RNA MALAT1. Cellular Physiology and Biochemistry, 2017, 42, 2194-2206.	1.6	66
49	Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations. Annals of Hematology, 2017, 96, 1945-1948.	1.8	7
50	Expression of the Î²3 subunit of Na+/K+-ATPase is increased in gastric cancer and regulates gastric cancer cell progression and prognosis via the PI3/AKT pathway. Oncotarget, 2017, 8, 84285-84299.	1.8	22
51	SjÃ¶grenâ€™s Syndrome Complicated by Myeloid/Natural Killer Cell Precursor Acute Leukemia: Case Report and Review of the Literature. Case Reports in Hematology, 2016, 2016, 1-4.	0.4	1
52	Outcomes of Transvenous Lead Extraction for Cardiovascular Implantable Electronic Device Infections in Patients With Prosthetic Heart Valves. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	14
53	Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspaseâ€3â€mediated cleavage of the AML1â€ETO oncoprotein. Cancer Medicine, 2016, 5, 3205-3213.	2.8	13
54	MicroRNA-150 negatively regulates the function of CD4+ T cells through AKT3/Bim signaling pathway. Cellular Immunology, 2016, 306-307, 35-40.	3.0	29

#	Article	IF	Citations
55	Cytotoxic T Lymphocyte Antigen-4 Down-Regulates T Helper 1 Cells by Increasing Expression of Signal Transducer and Activator of Transcription 3 in Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 212-219.	2.0	10
56	MicroRNAâ€181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFNâ€Î³ production. American Journal of Hematology, 2015, 90, 998-1007.	4.1	32
57	Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-Î²B p65 subunit nuclear import. Biochemical and Biophysical Research Communications, 2015, 462, 326-331.	2.1	22
58	Cdc42 inhibitor ML141 enhances G-CSF-induced hematopoietic stem and progenitor cell mobilization. International Journal of Hematology, 2015, 101, 5-12.	1.6	19
59	Co-transplantation of Hematopoietic Stem Cells and Cxcr4 Gene-Transduced Mesenchymal Stem Cells Promotes Hematopoiesis. Cell Biochemistry and Biophysics, 2015, 71, 1579-1587.	1.8	9
60	Increased expression of T cell immune response cDNA 7 in patients with acute graft-versus-host disease. Annals of Hematology, 2015, 94, 1025-1032.	1.8	6
61	Decreased level of cytotoxic T lymphocyte antigen-4 (CTLA-4) in patients with acute immune thrombocytopenia (ITP). Thrombosis Research, 2015, 136, 797-802.	1.7	11
62	Stromal cells attenuate the cytotoxicity of imatinib on Philadelphia chromosome-positive leukemia cells by up-regulating the VE-cadherin/Î²-catenin signal. Leukemia Research, 2014, 38, 1460-1468.	0.8	8
63	Elevated levels of T-cell immune response cDNA 7 in patients with immune thrombocytopenia. Hematology, 2014, 19, 477-482.	1.5	7
64	The D14 and R138 ion pair is involved in dimeric arginine kinase activity, structural stability and folding. International Journal of Biological Macromolecules, 2014, 66, 302-310.	7.5	5
65	T273 plays an important role in the activity and structural stability of arginine kinase. International Journal of Biological Macromolecules, 2014, 63, 21-28.	7.5	4
66	A Murine Model of Hepatic Veno-occlusive Disease Induced by Allogeneic Hematopoietic Stem Cell Transplantation. Cell Biochemistry and Biophysics, 2013, 67, 939-948.	1.8	10
67	Adrenaline administration promotes the efficiency of granulocyte colony stimulating factor-mediated hematopoietic stem and progenitor cell mobilization in mice. International Journal of Hematology, 2013, 97, 50-57.	1.6	8
68	The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability. International Journal of Biological Macromolecules, 2013, 60, 186-195.	7.5	17
69	RNA interference-mediated silencing of NANOG leads to reduced proliferation and self-renewal, cell cycle arrest and apoptosis in T-cell acute lymphoblastic leukemia cells via the p53 signaling pathway. Leukemia Research, 2013, 37, 1170-1177.	0.8	18
70	The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation. Immunobiology, 2013, 218, 1505-1513.	1.9	19
71	Disrupting of E79 and K138 interaction is responsible for human muscle creatine kinase deficiency diseases. International Journal of Biological Macromolecules, 2013, 54, 216-224.	7.5	5
72	Overexpression of the Mesenchymal Stem Cell Cxcr4 Gene in Irradiated Mice Increases the Homing Capacity of These Cells. Cell Biochemistry and Biophysics, 2013, 67, 1181-1191.	1.8	41

#	Article	IF	Citations
73	CXCR4-transduced mesenchymal stem cells protect mice against graft-versus-host disease. Immunology Letters, 2012, 143, 161-169.	2.5	20
74	Amino acid residue E543 in JAK2 C618R is a potential therapeutic target for myeloproliferative disorders caused by JAK2 C618R mutation. Archives of Biochemistry and Biophysics, 2012, 528, 57-66.	3.0	10
75	Infusion of Endothelial Progenitor Cells Accelerates Hematopoietic and Immune Reconstitution, and Ameliorates the Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation. Cell Biochemistry and Biophysics, 2012, 64, 213-222.	1.8	30
76	Novel Approach to Generate Genetically Engineered, Sortable, Î”NGFR-Tagged Mouse Th17 Cells. Cell Biochemistry and Biophysics, 2012, 64, 233-240.	1.8	0
77	Effects of High-Dose Dexamethasone on Regulating Interleukin-22 Production and Correcting Th1 and Th22 Polarization in Immune Thrombocytopenia. Journal of Clinical Immunology, 2012, 32, 523-529.	3.8	43
78	Irradiation induces homing of donor endothelial progenitor cells in allogeneic hematopoietic stem cell transplantation. International Journal of Hematology, 2012, 95, 189-197.	1.6	12
79	Elevated plasma IL-22 levels correlated with Th1 and Th22 cells in patients with immune thrombocytopenia. Clinical Immunology, 2011, 141, 121-123.	3.2	29
80	Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. International Journal of Hematology, 2011, 93, 91-98.	1.6	87
81	Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation. Leukemia Research, 2010, 34, 1374-1382.	0.8	24